| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00802321 | Alcohol Related Disorders|Alcoholism|Alcohol Abuse | Drug: Dutasteride | UConn Health|National Institutes of Health (NIH)|National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 2006-04-01 | 2010-09-22 |
| NCT01004809 | Alopecia | Drug: Dutasteride | GlaxoSmithKline | | 2010-04-01 | 2014-07-31 |
| NCT00985738 | Prostate Cancer | Drug: Dutasteride|Other: Placebo | University of Colorado, Denver|GlaxoSmithKline | Phase 2 | 2009-09-01 | 2016-04-15 |
| NCT00706966 | Nonmalignant Neoplasm|Prostate Cancer | Drug: dutasteride | University of California, San Francisco | | 2005-06-01 | 2013-12-02 |
| NCT01525914 | Prostate Cancer | Drug: Dutasteride | Sunnybrook Health Sciences Centre|Toronto Sunnybrook Regional Cancer Centre | 2010-05-01 | 2012-02-02 |
| NCT00805701 | Prostate Cancer | Drug: avodart|Drug: Placebo | Bay State Clinical Trials, Inc.|GlaxoSmithKline | Phase 4 | 2009-01-01 | 2014-05-12 |
| NCT01957189 | Prostatic Hyperplasia | Drug: Dutasteride and Tamsulosin | GlaxoSmithKline | Phase 1 | 2013-10-01 | 2017-01-16 |
| NCT00382356 | Benign Prostatic Hypertrophy | Drug: Dutasteride | North Florida/South Georgia Veterans Health System | | 2004-11-01 | 2012-10-18 |
| NCT01262287 | Alcoholism|Alcohol Abuse|Alcohol Dependence | Drug: Dutasteride|Drug: Placebo | UConn Health|National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 4 | 2011-01-01 | 2017-02-09 |
| NCT02578953 | Prostatic Hyperplasia | Drug: Dutasteride-Test product|Drug: Dutasteride-Reference product | GlaxoSmithKline | Phase 1 | 2015-09-01 | 2017-01-25 |
| NCT00441116 | Alopecia|Androgenetic Alopecia | Drug: Dutasteride 0.5mg oral tablets | GlaxoSmithKline | Phase 3 | 2006-12-01 | 2011-08-11 |
| NCT00303446 | Kennedy's Disease|Spinal and Bulbar Muscular Atrophy | Drug: Dutasteride|Drug: Placebo | National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC) | Phase 2 | 2006-03-01 | 2011-01-25 |
| NCT01254071 | Prostatic Hyperplasia | Drug: Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg) | GlaxoSmithKline | Phase 1 | 2010-09-01 | 2016-11-30 |
| NCT00363311 | Neoplasms, Prostate | Drug: Dutasteride|Drug: Matching placebo | GlaxoSmithKline | Phase 4 | 2006-07-01 | 2016-11-30 |
| NCT00553878 | Prostate Cancer | Drug: Dutasteride | Canadian Urology Research Consortium|GlaxoSmithKline | Phase 2|Phase 3 | 2007-03-01 | 2016-10-13 |
| NCT00853697 | Prostate Cancer|Castration-resistant, Metastatic | Other: testosterone (AndroGel) with the 5-reductase inhibitor dutasteride | Memorial Sloan Kettering Cancer Center|GlaxoSmithKline|University of Washington | Phase 2 | 2009-03-01 | 2015-10-28 |
| NCT00673127 | Prostate Cancer | Drug: Ketoconazole, Hydrocortisone and Dutasteride | Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Dana-Farber Cancer Institute|Sunnybrook Health Sciences Centre|Oregon Health and Science University|M.D. Anderson Cancer Center|Sidney Kimmel Comprehensive Cancer Center | Phase 2 | 2005-02-01 | 2015-04-20 |
| NCT01471678 | Prostatic Hyperplasia | Drug: Dutasteride (0.5mg)|Drug: FDC product of dutasteride (0.5mg) and tamsulosin HCl (0.2mg)|Drug: Harnal D Tablets and Harnal Capsules (both comprising 0.2 mg tamsulosin HCl) | GlaxoSmithKline | Phase 1 | 2011-06-01 | 2016-11-30 |
| NCT01831791 | Alopecia | Drug: Dutasteride 0.5 mg | GlaxoSmithKline | Phase 3 | 2013-04-01 | 2015-02-26 |
| NCT00194675 | Hypogonadism|Benign Prostatic Hyperplasia | Drug: Dutasteride|Drug: Testosterone gel|Drug: Placebo dutasteride | University of Washington|GlaxoSmithKline|Seattle Institute for Biomedical and Clinical Research|VA Office of Research and Development|Solvay Pharmaceuticals | Phase 4 | 2005-03-01 | 2012-07-16 |
| NCT00827814 | Benign Prostatic Hyperplasia | Drug: Dutasteride | Samsung Medical Center|GlaxoSmithKline | Phase 4 | 2006-06-01 | 2009-06-08 |
